Navigation Links
Paragon Quadra RG 100 (paflufocon D)

ProductsParagon Quadra RG 100 (paflufocon D)
Company Paragon Vision Sciences
Item Paragon Quadra RG 100 (paflufocon D)
Features CRT has been made possible by five new technologies:
  • Advances in multicurve GP lenses specifically designed to facilitate the safe redistribution of corneal tissue while sleeping.
  • Advances in computer controlled lathing technology, allowing complex lens designs to be consistently fabricated and, in the case of Paragon CRT, with seamless, polishless surfaces and on a tolerance level measured in microns.
  • The development of stable, wettable, high Dk materials that can be safely worn overnight.
  • Advances in computerized corneal mapping techniques providing more precise fitting and follow-up patients.
  • A greater understanding of how corneal reshaping works and the tissues involved in the process.
Description These are rigid gas permeable contact lenses used for corneal refractive therapy, a process that temporarily corrects nearsightedness (myopia). The patient wears the lenses overnight while sleeping and removes them upon wakening. During the day, nearsightedness is corrected or greatly reduced

The Paragon CRT and Quadra RG contact lenses apply slight pressure to the center of the cornea, causing it to temporarily flatten. The flattened cornea redirects light onto the back surface of the eye (the retina) at an angle that can compensate for nearsightedness. Since the cornea is elastic, it gradually regains its shape throughout the day (causing nearsightedness to return). Usually, patients must wear the lenses every night to maintain corrected vision.

The lenses are used for the temporary correction of nearsightedness. They can be used by patients with or without vision distortion (astigmatism). They are usually worn overnight as part of a corneal refractive therapy program. When the lenses are removed each morning, they must be cleaned using a chemical disinfection system.

Why Paragon CRT is the right choice for your practice:

  • Paragon CRT brings opportunity for your practice growth and patient retention.
  • Take advantage! Refractive surgery has created a market of patients wanting freedom from glasses and daytime contacts without surgery.
  • Paragon CRT sets the standard for Corneal Refractive Therapy not only with the first FDA approval for overnight CRT but also by offering a Total System which includes a Diagnostic Dispensing System and a Complete Practice Management Program.
  • With no age restrictions, Paragon CRT is the perfect option for active kids and teens who arent eligible for refractive surgery.
  • Paragon CRT rounds out your practice and is the perfect complement for refractive surgery and 30-day continuous wear lenses.
Info Paragon Vision Sciences
Customer Service: (800) 528-8279
Web site: http://www.paragonvision.com

Related medicine products :

1. Paragon CRT 100 (paflufocon D)
2. Paragon CRT (paflufocon B)
3. Paragon Quadra RG (paflufocon B)
4. Paragon CZE 2000 Capillary Electrophoresis System
5. Paragon™ Nitinol Paired Helical Basket
6. Paragonimiasis Antibody
7. Webster Quadrapolar Standard Deflectable Catheters
8. Quadra-Coil® Multi-Length Ureteral Stents
9. QuadraLase™
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products:
(Date:11/21/2014)... CDT PLUS! 2015 represents ... includes everything needed to process dental insurance claims. ... , CDT 2015 codes are mandatory for reporting dental ... December 31, 2014. Dental professionals must use HIPAA mandated ... claims. There are significant changes in the CDT coding ...
(Date:11/21/2014)... 21, 2014 TopConsumerReviews.com recently awarded ... industry leader in the relief of depression ... feelings of sadness and depression each year and ... choices. Often, prescription drugs can produce worse side ... are expensive and require regular follow-up visits with ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 According ... issued on June 11th, 2014, the inflating system ... rupture when the airbag inflates. The force of inflation ... shrapnel, and the metal shards may pierce the airbag’s ... vehicle’s cabin. , According to a Bloomberg Business ...
(Date:11/21/2014)... London, UK (PRWEB) November 21, 2014 ... only ISO verified healthcare professional panel, today announced two important ... appointment of Roni DasGupta as President of Market Research, Americas ... Market Research, Europe. , Ms. DasGupta joined M3 ... President and most recently Head of Sales. Roni has ...
(Date:11/21/2014)... Dennis Thompson HealthDay ... Injecting beads of gel into the wall of a still-beating ... with severe heart failure, according to a new study. ... oxygen levels and were able to walk hundreds of feet ... Douglas Mann. He is chief of the cardiovascular division at ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3
... to open blocked heart arteries a key question has ... expensive drug, abciximab, justified over use of the less-expensive ... be published in the current edition of Value in ... an e-publication, offers clinicians the first large-scale contemporary study ...
... On the Wings to Patient Safety: Innovative Solutions and Tools set ... ... Mich., Sept. 10 The Risk Management and,Patient Safety Institute (RM&PSI) ... conference. The RM&PSI, a,subsidiary of FinCor Holdings Inc. (http://www.fincorholdings.com ), ...
... accuracy and turn-around time for reimbursement, WAYNE, ... in,health information management (HIM) services and technologies, today,announced ... 2X. The key enhancement to PrecyseCode 2X is ... of the medical record,and greater efficiency and speed ...
... Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud Case ... Sept. 10 Judge Morris E.,Lasker of the ... has,granted final approval of a $52.5 million settlement ... Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: SEPR ...
... well known healthcare industry executive to start October ... Corporation,(NYSE: STE ) today announced that its ... 53, president and chief executive officer, effective,October 1, ... Company,s Board,effective that date. (Photo: http://www.newscom.com/cgi-bin/prnh/20070910/CLM134 ...
... Institute are the first to discover a mechanism that ... cycle and survival. Their research may result in identification ... , The results of the study appear ... PhD, assistant professor of hematology and oncology at Emory ...
Cached Medicine News:Health News:The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 3Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 3Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 4Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 5Health News:Emory researchers identify signaling protein for multiple myeloma 2Health News:Emory researchers identify signaling protein for multiple myeloma 3
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3